Wontech, a laser and energy-based medical solutions company, is accelerating its strategic business expansion by establishing footholds in key Latin American markets. The company has secured regulatory approvals for its Lavieen and V-Laser devices in Mexico, following earlier approvals in Brazil, positioning itself in the two largest medical aesthetics markets in the region, which together account for over half of Latin America's medical aesthetics market.
Market signal
Wontech's simultaneous entry into Brazil and Mexico signals a deliberate strategy to capture the dominant share of Latin America's medical aesthetics market. By securing approvals in both countries, the company creates a dual-hub model that can serve as a springboard for broader regional distribution. For overseas buyers and distributors, this indicates a growing commitment to regulatory compliance and market-specific adaptation, which are critical for long-term partnerships in the region.
Product portfolio and clinical applications
The V-Laser device, based on 1064nm and 532nm dual wavelengths, is designed for a range of indications including non-invasive incision, excision, removal, hemostasis, and coagulation of soft tissue in surgical procedures. In Mexico, Wontech now offers both Lavieen for skin rejuvenation and pigmentation treatment, and V-Laser for vascular and pigmented lesion therapy. This combined portfolio allows the company to address diverse clinical needs across local medical institutions.
Pre-sales and training groundwork
Before obtaining regulatory certification, Wontech initiated pre-sales activities with its local distributor in Mexico. In May, the company invited 15 Mexican physicians to South Korea for intensive V-Laser training, laying the foundation for immediate revenue conversion upon market entry. This proactive approach reduces the typical lag between approval and commercial sales, a key advantage for distributors seeking rapid market penetration.
Regulatory and channel signals
Latin America's medical aesthetics market is characterized by varying regulatory frameworks across countries, making approval speed a critical factor for market entry. Wontech's strategy of replicating its Brazil-proven approach in Mexico creates a unified business structure linking the two largest markets. The company plans to leverage product competitiveness and clinical references from both hubs to strengthen physician training, academic activities, and marketing programs across the region.
What buyers should watch
Distributors and clinic buyers in Latin America should monitor Wontech's expanding product lineup and its dual-market regulatory strategy. The company's investment in local physician training and pre-sales activities suggests a readiness to support channel partners with clinical education and marketing resources. For those seeking reliable suppliers with a clear regional expansion roadmap, Wontech's dual-hub model offers a lower-risk entry point into the broader Latin American market.
Source: Read the original report | Published: June 02, 2026